Juvenescence

The company offers solutions for research needs.

Juvenescence appointed Eileen Jennings-Brown as Chief Technology Officer to lead AI and technology strategy. It also announced a partnership and facilities with Masdar City in Abu Dhabi.

Juvenescence completed a Phase 1 trial of PAI-1 inhibitor MDI-2517, reporting good safety and tolerability. It planned a Phase 2 proof-of-concept trial for metabolic and fibrotic disease; Carmel Nanthakumar joined as VP, Translational Biology.

Catherine McClinton is a senior operations leader with over 30 years of clinical expertise. Her experience includes operational delivery for global Phase I through Phase II/III research studies, with a focus on data quality, regulatory readiness and trial delivery.

Rosalba Perrone is a Senior Research Scientist at Juvenescence with expertise in immune-metabolism and aging biology. Rosalba has over six years in biotech and has worked on early-stage therapeutics, translational biology, preclinical study design, and anti-inflammatory assays.

Carmel Nanthakumar is a senior scientific leader in drug discovery, translational biology and clinical development, with over 20 years of experience at GSK, AstraZeneca and Merck. At GSK, she led global teams across preclinical and clinical development.

Eileen Jennings-Brown is Chief Technology & Transformation Officer at Juvenescence. She leads its technology strategy and enterprise transformation, including development of AI-enabled drug discovery capabilities and digital foundations for global scaling.

The page invites inquiries to connect with a team member and directs product inquiries to care@juvlabs.com.

The company develops medicines that target core aging mechanisms to extend healthy lifespan and treat or prevent age-related diseases.

Juvenescence Therapeutics Limited provides services through its website, www.JuvTherapeutics.com. The terms state that visiting the site or making a purchase constitutes engagement with the service and agreement to the terms.